title: Pars plana vitrectomy for cystoid macular edema secondary to sarcoid uveitis.
abstract: OBJECTIVE
  To examine the results of pars plana vitrectomy for cystoid macular edema secondary to sarcoid uveitis resistant to medical treatment.
  
  
  METHODS
  Retrospective, interventional, noncomparative case series.
  
  
  METHODS
  Fourteen consecutive subjects (18 eyes) with cystoid macular edema associated with sarcoid uveitis resistant to medical treatment.
  
  
  METHODS
  All eyes underwent pars plana vitrectomy. Nine eyes also underwent peeling of the epiretinal membrane or removal of the posterior vitreous cortex.
  
  
  METHODS
  Status of macular edema, visual acuity, and complications.
  
  
  RESULTS
  Ten eyes (56%) improved 2 or more lines of Snellen visual acuity within 12 months. Six eyes (33%) remained unchanged, within a line of preoperative Snellen visual acuity, and two eyes (11%) worsened by 2 or more lines of Snellen visual acuity. Slit-lamp biomicroscopy showed that cystoid macular edema had resolved in 14 eyes (78%) within 9 months postoperatively. One eye (6%) had minimal edema, whereas three eyes (17%) remained unchanged biomicroscopically at the final visit. Postoperative complications included cataract formation, glaucoma, optic nerve atrophy, epiretinal membrane formation, and tractional retinal detachment. No severe postoperative inflammation was noted.
  
  
  CONCLUSIONS
  Pars plana vitrectomy seems to have a beneficial effect on cystoid macular edema caused by sarcoidosis resistant to medical treatment.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Kiryu
authors.forename: M
authors.initials: M
authors.lastname: Kita
authors.forename: T
authors.initials: T
authors.lastname: Tanabe
authors.forename: K
authors.initials: K
authors.lastname: Yamashiro
authors.forename: N
authors.initials: N
authors.lastname: Miyamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ieki
mesh_terms: D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008269:Macular Edema / Q000209:etiology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D012507:Sarcoidosis / Q000150:complications*; D014605:Uveitis / Q000150:complications* / Q000188:drug therapy; D014792:Visual Acuity; D014821:Vitrectomy
chemical_list: D005938:Glucocorticoids; D001623:Betamethasone; D011241:Prednisone